Research programme: growth hormone-related compounds - Neuren

Drug Profile

Research programme: growth hormone-related compounds - Neuren

Alternative Names: NNZ-3006

Latest Information Update: 23 Feb 2007

Price : $50

At a glance

  • Originator Neuren Pharmaceuticals
  • Class Growth hormones
  • Mechanism of Action Insulin-like growth factor I inhibitors; Somatotropin receptor agonists; Somatotropin receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Preclinical Cancer; Metabolic disorders; Obesity; Somatotropin deficiency

Most Recent Events

  • 18 Apr 2006 This programme is still in active development
  • 27 Jul 2005 Preclinical trials in Growth disorders in USA (unspecified route)
  • 13 Jan 2005 Preclinical trials in Cancer in New Zealand (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top